These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 8108927)
1. High cure rate of invasive fungal infections in immunocompromised children using ambisome. Ringdén O; Tollemar J; Dahllöf G; Tydén G Transplant Proc; 1994 Feb; 26(1):175-7. PubMed ID: 8108927 [No Abstract] [Full Text] [Related]
2. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Tollemar J; Ringdén O; Andersson S; Sundberg B; Ljungman P; Tydén G Bone Marrow Transplant; 1993 Dec; 12(6):577-82. PubMed ID: 8136741 [TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Ng TT; Denning DW Arch Intern Med; 1995 May; 155(10):1093-8. PubMed ID: 7748054 [TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children. Ringdén O; Tollemar J Mycoses; 1993; 36(5-6):187-92. PubMed ID: 8264715 [TBL] [Abstract][Full Text] [Related]
5. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation. Ringdén O; Andström EE; Remberger M; Dahllöf G; Svahn BM; Tollemar J Pediatr Transplant; 1997 Nov; 1(2):124-9. PubMed ID: 10084772 [TBL] [Abstract][Full Text] [Related]
6. Conventional vs. liposomal amphotericin B in immunosuppressed children. Zoubek A; Emminger W; Emminger-Schmidmeier W; Peters C; Pracher E; Grois N; Gadner H Pediatr Hematol Oncol; 1992; 9(2):187-90. PubMed ID: 1524992 [TBL] [Abstract][Full Text] [Related]
7. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial. Tollemar J; Höckerstedt K; Ericzon BG; Jalanko H; Ringdén O Transplant Proc; 1995 Feb; 27(1):1195-8. PubMed ID: 7878847 [No Abstract] [Full Text] [Related]
8. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B]. Viscoli C; Castagnola E Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741 [TBL] [Abstract][Full Text] [Related]
9. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis. Cordonnier C; Bresnik M; Ebrahimi R Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Ringdén O; Meunier F; Tollemar J; Ricci P; Tura S; Kuse E; Viviani MA; Gorin NC; Klastersky J; Fenaux P J Antimicrob Chemother; 1991 Oct; 28 Suppl B():73-82. PubMed ID: 1778894 [TBL] [Abstract][Full Text] [Related]
11. [Fungal infections in patients undergoing solid organ transplantation]. Muñoz P; Bouza E Enferm Infecc Microbiol Clin; 1997 May; 15 Suppl 2():34-50. PubMed ID: 9312298 [No Abstract] [Full Text] [Related]
12. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed. Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210 [TBL] [Abstract][Full Text] [Related]
13. Management of immunocompromised patients with evidence of an invasive mycosis. Walsh TJ Hematol Oncol Clin North Am; 1993 Oct; 7(5):1003-26. PubMed ID: 8226563 [TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin-B (AmBisome) for treatment of disseminated fungal infections in two infants of very low birth weight. Lackner H; Schwinger W; Urban C; Müller W; Ritschel E; Reiterer F; Kuttnig-Haim M; Urlesberger B; Hauer C Pediatrics; 1992 Jun; 89(6 Pt 2):1259-61. PubMed ID: 1594386 [No Abstract] [Full Text] [Related]
15. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Ringdén O; Andström E; Remberger M; Svahn BM; Tollemar J Bone Marrow Transplant; 1994; 14 Suppl 5():S10-4. PubMed ID: 7703925 [TBL] [Abstract][Full Text] [Related]
16. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575 [TBL] [Abstract][Full Text] [Related]
17. Use of liposomal amphotericin B in bone marrow transplant. Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256 [TBL] [Abstract][Full Text] [Related]
18. Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation. Mattei D; Mordini N; Lo Nigro C; Ghirardo D; Ferrua MT; Osenda M; Gallamini A; Bacigalupo A; Viscoli C Bone Marrow Transplant; 2002 Dec; 30(12):967-70. PubMed ID: 12476292 [TBL] [Abstract][Full Text] [Related]
19. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954 [TBL] [Abstract][Full Text] [Related]
20. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. Chanock SJ; Walsh TJ Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S15-20. PubMed ID: 8971401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]